Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
Completed · Phase 2 · NCT02910583
Conditions: Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $82,750
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 323
About the trial
- Sponsor
- Pharmacyclics LLC. (with Janssen Research & Development, LLC)
- Tested
- ibrutinib (drug), venetoclax (drug), Placebo (drug)
- Dates
- Started 2016-09-28; completion 2024-03-27
- Results posted
- Yes
This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or SLL.
From ClinicalTrials.gov, last updated 2026-09-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $82,750 in research payments for this study in 2025 (13 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Tanya Siddiqi, M.D. Hematology · Duarte, CA
- John N. Allan, M.D. Hematology & Oncology · New York, NY
- Ian W. Flinn, M.D. Hematology & Oncology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Weill Medical College of Cornell Un $67,227
- City of Hope National Medical Ctr $10,984
- Sarah Cannon Research Institute $4,539
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.